Yes, clozapine (Clozaril) significantly reduces suicide risk in patients with schizophrenia or schizoaffective disorder.
Clozapine is the only antipsychotic with FDA approval and strong guideline support specifically for reducing suicidal behavior in schizophrenia, and should be used when suicide risk remains substantial despite other treatments. 1
Evidence Base
The 2020 American Psychiatric Association guidelines provide the strongest recommendation: clozapine should be used in patients with schizophrenia when the risk for suicide attempts or suicide remains substantial despite other treatments (Grade 1B recommendation). 1 This is echoed by the most recent 2025 VA/DoD guidelines, which suggest clozapine to reduce suicide attempts in patients with schizophrenia or schizoaffective disorder who have either suicidal ideation or a history of suicide attempts (weak for recommendation). 2
The landmark InterSePT trial (2003) demonstrated clozapine's superiority over olanzapine in 980 high-risk patients with schizophrenia or schizoaffective disorder. Clozapine reduced suicidal behavior by 24% (hazard ratio 0.76, p=0.03), with significantly fewer suicide attempts (34 vs 55), fewer hospitalizations to prevent suicide (82 vs 107), and fewer rescue interventions needed (118 vs 155). 3 A meta-analysis found clozapine reduced overall suicidal behaviors by 3.3-fold compared to other treatments (RR 3.3,95% CI 1.7-6.3, p<0.0001). 4
Clinical Application Algorithm
When to use clozapine for suicide prevention:
Primary indication: Patient with schizophrenia or schizoaffective disorder who has persistent suicidal ideation or history of suicide attempts despite trials of at least 2 other antipsychotics 1
Consider earlier use: In patients with treatment-resistant schizophrenia who also have elevated suicide risk, clozapine addresses both issues simultaneously 1
Monitoring requirements: The mandatory REMS program with frequent visits may actually contribute to suicide reduction through increased clinical contact and monitoring 5
Critical Caveats
The evidence is specific to schizophrenia and schizoaffective disorder—clozapine's anti-suicidal effects have NOT been demonstrated in mood disorders, which constitute the majority of suicide deaths. 6 The 2019 VA/DoD guidelines explicitly note this limitation. 5
Abrupt clozapine discontinuation carries significant suicide risk. Case reports document completed suicides following clozapine discontinuation in previously stable patients. 7 Any decision to stop clozapine in a patient with prior suicidality requires extremely careful risk assessment and close monitoring during the transition period.
Proposed Mechanisms
Clozapine's anti-suicidal effects may be independent of its antipsychotic properties and could involve: direct antidepressant action, improved cognitive function and insight, reduced hopelessness, diminished substance abuse (which is itself a suicide risk factor), and improved treatment adherence. 8, 9 The frequent monitoring required by the REMS program provides additional protective surveillance. 5
Practical Implementation
Start clozapine using standard titration protocols with concurrent metformin to mitigate weight gain. 10 Target plasma levels of at least 350 ng/mL for therapeutic response. 10 The anti-suicidal benefits emerge during maintenance treatment rather than acutely—this is not a rapid intervention like ketamine for acute suicidal crises. 5
Bottom line: For patients with schizophrenia or schizoaffective disorder who remain at substantial suicide risk despite other treatments, clozapine is the evidence-based choice and should not be delayed due to monitoring concerns, as the mortality benefit outweighs the risks. 1